openPR Logo
Press release

Global Cancer mTOR Inhibitors Market and Clinical Pipeline Outlook 2022

11-08-2017 12:59 PM CET | Health & Medicine

Press release from: Kuick Resarch

Global Cancer mTOR Inhibitors Market and Clinical Pipeline

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-global-cancer-mtor-inhibitors-market-and-clinical-pipeline-outlook-2022.php

Table of Contents

1. Mammalian Target of Rapamycin Inhibitors (mTOR) - The Future of Cancer Growth Blockers
1.1 Preliminary Insight to mTOR Inhibitors
1.2 History and Evolution of the mTOR Inhibitors

2. mTOR Signalling Pathway: Their Role and Significance in Cancer
2.1 mTOR Signalling: A Vital Function in Cell Growth
2.2 mTOR Signalling Pathway and Tumorigenesis

3. Principles of mTOR inhibitors in Cancer Therapy
3.1 Activation of mTOR/pI3K pathway in Cancer
3.2 Potential of mTOR as a Targeted Therapy
3.3 Global - Cancer MTOR Inhibitors Clinical Pipeline Overview

4. Working Mechanism of mTOR Inhibitors in Cancer Therapy
4.1 Effect of mTOR inhibitors in Cancer Cells
4.2 Effects of mTOR inhibitors on Tumor Angiogenesis

5. Clinical Status and Application of mTOR inhibitors in Various Types of Cancer
5.1 Breast Cancer
5.1.1 HER2-Positive Breast Cancer
5.1.2 HER-2 Negative Breast Cancer
5.2 Hematological Malignancy
5.2.1 Acute Myeloid Leukemia
5.2.2 Chronic Myelogenous Leukemia
5.2.3 Acute Lymphoblastic Leukemia
5.2.4 Multiple Myeloma
5.2.5 Lymphoma
5.3 Neuroendocrine Tumors
5.4 Hepatocellular Carcinoma
5.5 Glioblastoma (Brain Tumor)
5.6 Other Cancers/Tumors Where mTOR Inhibitors Could be Effective
5.6.1 Non-small Cell Lung Cancers
5.6.2 Colon Cancer

6. Recent Advances in mTOR Inhibitor Cancer Therapy
6.1 Drug Combinations as a Therapeutic Approach for mTORC1 Inhibitors in Human Cancer
6.2 Optimizing Activity of Rapalogs Using Combinations with Other Anticancer Drugs

7. Global Demand and Opportunities in the mTOR Inhibitor Market

8. Global andndash; Cancer MTOR Inhibitors Clinical Pipeline by Company, Indication and Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III

9. Marketed Cancer MTOR Inhibitors Clinical Insight
9.1 Temsirolimus (Torisel)
9.2 Everolimus (Absorb, Affinitor, Affinitor Dispersible, Afinitor, Afinitor Disperz, Certican, Esprit BVS, Promus, Promus Element, Promus Premier, Synergy, Votubia, Xience Prime, Xience V, Xience Xpedition, Xience nano and Zortress)

10. mTOR Inhibitor andndash; Price Analysis by Under Development and Approved Inhibitors
10.1 mTOR Inhibitors Price by Product Under Development
10.1.1 Dactolisib(BEZ 235, NVP-BEZ 235)
10.1.2 Rapamycin
10.1.3 Temsirolimus
10.1.4 PI-103
10.1.5 AZD 8055
10.1.6 Torkinib (pp242)
10.1.7 Ridaforolimus (Deforolimus, MK-8669)
10.1.8 MLN0128 (INK128)
10.1.9 Omipalisib (GSK2126458, GSK458)
10.1.10 Gedatolisib (PF-05212384, PKI-587)
10.1.11 Other Promising mTOR Inhibitors
10.2 Approved and Commercialized Cancer Therapy mTOR Inhibitor Price Analysis
10.2.1 Afinitor/Votubia
10.2.2 Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor
10.2.3 Torisel (Temsirolimus)
10.2.4 Evertor andndash; Everolimus by Biocon

11. Market Performance Analysis of mTOR Inhibitors
11.1 Market Performance by Industry
11.1.1 Afinitor by Novartis
11.1.2 Toricel by Pfizer
11.1.3 Evertor by Biocon

12. Comparative Cost Analysis of mTOR Inhibitors with Other Cancer Therapeutics
12.1 Comparative Cost Analysis by other Popular Cancer Therapy Drugs
12.2 Comparative Cost Analysis with Traditional Cancer Therapeutics

13. Regional Analysis of mTOR Inhibitor Market
13.1 North America
13.2 Europe
13.3 Asia Pacific
13.4 Rest of the World

14. Global mTOR Inhibitor Market Dynamics
14.1 Driving Factors of the Global mTOR Inhibitor Market
14.2 Restraining Factors of the Global mTOR Inhibitor Market

15. Future Forecast and Growth Projections of Global mTOR Inhibitors Market

16. Competitive Landscape
16.1 Abraxis BioScience
16.2 Adimab
16.3 Celgene Corporation
16.4 Celator Pharmaceuticals
16.5 Eli Lilly
16.6 Exelixis
16.7 GlaxoSmithKline
16.8 HEC Pharm
16.9 Intellikine
16.10 Novartis
16.11 Oneness Biotech
16.12 PIQUR Therapeutics
16.13 Semafore Pharmaceuticals
16.14 Takeda
16.15 Wyeth

Figure 1-1: mTOR Inhibitors Timeline
Figure 2-1: Normal Functioning of the mTOR Pathway
Figure 3-1: Activators of the mTOR Pathway
Figure 3-2: Global andndash; Cancer MTOR Inhibitors Clinical Pipeline by Phase (%), 2017 till 2022
Figure 3-3: Global andndash; Cancer MTOR Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 3-4: Global andndash; Cancer MTOR Inhibitors Clinical Pipeline by Phase (%), 2017 till 2022
Figure 3-5: Global andndash; Cancer MTOR Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 4-1: mTOR Inhibitors in Action
Figure 5-1: mTOR inhibitors in Breast Cancer
Figure 5-2: The mTOR (PAM) Pathway and Inhibitors of the pathway tested in phase I-III Clinical Trials on Solid Tumors and Breast Cancer
Figure 5-3: Action of Inhibitors under Clinical Development
Figure 6-1: Higher Efficacy of Therapeutics Achieved by using mTOR inhibitor in Combination
Figure 7-1: Global - Breast Cancer Incidence (Per 100,000 females), 2016
Figure 7-2: Global - Kidney Cancer Prevalence (Total Incidence Recorded), 2016
Figure 7-3: Global-Hepatocellular Carcinoma by Region ( per 100, 000),2016
Figure 10-1: Dactolisib- Price Analysis (US$/mg),2017
Figure 10-2: Rapamycin - Price Analysis (US$/mg), 2017
Figure 10-3: Temsirolimus - Price Analysis (US$/gm.), 2017
Figure 10-4: PI-103 Price Analysis (US$/gm.), 2017
Figure 10-5: AZD 8055-Price analysis (US$/mg), 2017
Figure 10-6: Torkinib-Price Analysis (US $/mg), 2017
Figure 10-7: Ridaforolimus- Price Analysis (US$/mg), 2017
Figure 10-8: MLNO 128- Price Analysis (US$/mg), 2017
Figure 10-9: Omipalisib - Price Analysis (US$/mg), 2017
Figure 10-10: Gedatolisib - Price Analysis (US$/mg), 2017
Figure 10-11: Apitolisib (GDC-0980, RG7422) - Price Analysis (US$/mg), 2017
Figure 10-12: Vistusertib-(AZD2014 (GDC-0980, RG7422) - Price Analysis (US$/mg), 2017
Figure 10-13: Voxtalisib -AZD2014 (GDC-0980, RG7422) - Price Analysis (US$/mg), 2017
Figure 10-14: OSI-27 price analysis (US$/mg), 2017
Figure 10-15: US - Price Analysis of Afinitor by quantity (28 Tablet Packet), 2017
Figure 10-16: Price Analysis- Everolimus Standalone Therapy (US$), 2017
Figure 10-17: Afinitor Disperz - Price Analysis by Quantity (US$), 2017
Figure 10-18: Temsirolimus - Cost Analysis (US$), 2017
Figure 10-19: Cost Analysis andndash; Evertor (Everolimus by Biocon)(US$), 2017
Figure 11-1: Global andndash; Afinitor Sales (US$ Million), 2013-2016
Figure 11-2: Global - Toricel Sales (US$ Million), 2012-2016
Figure 11-3: Global andndash; Evertor Sales (US$ Million), 2012-2016
Figure 12-1: Comparative Cost Analysis andndash; Afinitor (mTOR inhibitor) v/s Other Recommended Therapy for Breast Cancer (US$/Month), 2017
Figure 12-2: Comparative Cost Analysis andndash; Everolimus and Temsirolimus (mTOR inhibitors) v/s Other Recommended Therapy for Kidney Cancer (US$/Month), 2017
Figure 12-3: Comparative Cost Analysis andndash; Average mTOR Inhibitor Therapy v/s Traditional Cancer Therapy Cost
Figure 13-1: Global- mTOR Inhibitor Market by Region (%), 2016 and 2022
Figure 14-1: Global - Driving Factors of the mTOR Inhibitor Market
Figure 14-2: Global - Challenging Factors of the Global mTOR Inhibitor Market
Figure 14-3: Afinitor - Patent Expiration, 2017-2020



Table 3-1: mTOR Overexpression and Related Tumors
Table 11-1: Asia- Leading Manufactures and Suppliers of Everolimus

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Cancer mTOR Inhibitors Market and Clinical Pipeline Outlook 2022 here

News-ID: 807563 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Figure

Floralite - Reduce Fat & Get Attractive Figure How To Buy!
Floralite Have you been working on your eating routine without seeing the results that you are anticipating? There is indeed thing called Floralite diet pills. Advantages of Floralite Floralite One of various things to esteem about this thing is that it's made expressly for the Floralite diet. That is an epic notwithstanding considering the way that when you use a thing that is custom fitted to work with the movements
THE WORLD'S MOST CONTROVERSIAL ACTION FIGURE...EVER!
FOR IMMEDIATE RELEASE THE WORLD'S MOST CONTROVERSIAL ACTION FIGURE...EVER! Contact: William Hirsch - Schlock Toys @ +1-949-677-9353 or DocSchlock@SchlockToys.com Featured on Tomi with Fox News host Tomi Lahren! SCHLOCK TOYS join forces with Kickstarter to Make Toys Great Again! The Kickstarter campaign page can be found HERE: https://www.kickstarter.com/projects/schlocktoys/collectors-edition-talking-trump-2020-man-of-action-figure/description “What a great message to be sent, and I think Trump himself would love this and that he’d be excited about it!” - Tomi Lahren, Fox News “You
Macarons Market Latest Sales Figure Signals More Opportunities Ahead
Global Macarons Sales Market(Sales,Revenue and competitors Analysis of Major Market)from 2014-2026 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing investment structure of the Global Macarons Market. Some of the key players profiled in the study are La Dure,
Global Womens Figure Skates Market Growth 2019-2024
LP INFORMATION offers a latest published report on Womens Figure Skates Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Womens Figure Skates market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.
Figure Skating Equipment Market Report 2018: Segmentation by Type (Figure Skate …
Global Figure Skating Equipment market research report provides company profile for SP-Teri, Graf Skate, Riedell Shoes, Roces, American Athletic, Rollerblade, Winnwell, Dongguan King Line, Jackson Ultima, HD Sports(MK Blades, John Wilson), Edea, Risport Skates, Paramount Skates and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY
Long-lasting Performance Improvement with Key Figure Analysis
Vienna/Reutlingen, October 17, 2012 – Manz, a leading high-tech mechanical engineering company, is optimizing its processes in strategic sourcing in order to recognize the risks and potential associated with each supplier early on so that the sourcing department can react to them in time. POOL4TOOL’s customized eSolutions localize and analyze key figures that are relevant to the decision making process, and displays these figures in a comprehensive and transparent way.